Please use this identifier to cite or link to this item:
Title: Intravitreal Ranibizumab or Aflibercept After Bevacizumab in Diabetic Macular Edema: Exploratory Retrospective Analysis
Authors: Pessoa, Bernardete
Malheiro, Luísa
Carneiro, Inês 
Monteiro, Sílvia
Coelho, João
Coelho, Constança
Figueira, João 
Meireles, Angelina
Beirão, João Nuno Melo
Keywords: aflibercept; bevacizumab; diabetic macular edema; ranibizumab, refractory
Issue Date: 2021
Publisher: Dove Medical Press
Serial title, monograph or event: Clinical Ophthalmology
Volume: 15
Abstract: Aim: To evaluate the efficacy of switching from bevacizumab to ranibizumab or aflibercept in eyes with diabetic macular edema (DME) unresponsive to bevacizumab. Methods: Single-center retrospective comparative study of patients with DME unresponsive to intravitreal bevacizumab that was switched to ranibizumab or aflibercept. Best-corrected visual acuity (BCVA) and central foveal thickness (CFT) were analysed prior to and 4 months after the switch. Ocular coherence tomography (OCT) biomarkers were also analysed. Results: Fifty-six eyes from 40 patients were included in the study, 33 eyes switched to ranibizumab and 23 to aflibercept. A significant median CFT decrease was observed in both groups (p<0.001), with no between-group differences. BCVA gain was only significant in the ranibizumab group (p<0.001). None of the pre-baseline or baseline parameters were associated with the response to ranibizumab or aflibercept. Conclusion: In persistent DME unresponsive to bevacizumab, both anatomical and functional improvements were observed with ranibizumab whereas aflibercept only showed an anatomical improvement. NCT04018833.
ISSN: 1177-5467
DOI: 10.2147/OPTH.S280644
Rights: openAccess
Appears in Collections:FMUC Medicina - Artigos em Revistas Internacionais

Show full item record

Page view(s)

checked on Sep 18, 2023


checked on Sep 18, 2023

Google ScholarTM




This item is licensed under a Creative Commons License Creative Commons